133 related articles for article (PubMed ID: 37843345)
1. The relationship between the use of nucleos(t)ide analogs and metabolic parameters in patients with chronic hepatitis B.
Yakut A; Aladag M
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9315-9323. PubMed ID: 37843345
[TBL] [Abstract][Full Text] [Related]
2. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
3. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
5. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis.
Tong K; Chen M; Wang D; Dai H; Peng J; Zhang J; Zhou J; Chang Y; Huang W
Eur J Clin Pharmacol; 2024 Mar; 80(3):335-354. PubMed ID: 38197944
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
Dilokthornsakul P; Sawangjit R; Tangkijvanich P; Chayanupatkul M; Tanwandee T; Sukeepaisarnjaroen W; Sriuttha P; Permsuwan U
Appl Health Econ Health Policy; 2022 Jul; 20(4):587-596. PubMed ID: 35141850
[TBL] [Abstract][Full Text] [Related]
7. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
8. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Chon HY; Ahn SH; Kim YJ; Yoon JH; Lee JH; Sinn DH; Kim SU
Hepatol Int; 2021 Dec; 15(6):1328-1336. PubMed ID: 34799838
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
11. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Shaheen AA; AlMattooq M; Yazdanfar S; Burak KW; Swain MG; Congly SE; Borman MA; Lee SS; Myers RP; Coffin CS
Aliment Pharmacol Ther; 2017 Sep; 46(6):599-604. PubMed ID: 28707319
[TBL] [Abstract][Full Text] [Related]
13. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.
Yuan BH; Li RH; Huo RR; Li MJ; Papatheodoridis G; Zhong JH
J Gastroenterol Hepatol; 2022 May; 37(5):782-794. PubMed ID: 35080052
[TBL] [Abstract][Full Text] [Related]
14. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.
Yamashige D; Hosaka T; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2021 Nov; 56(11):1008-1021. PubMed ID: 34596753
[TBL] [Abstract][Full Text] [Related]
16. Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients.
Zhang Q; Liang J; Yin J; Jiang Y; Yu N; Liao X; Zhao S; Wu L; Fan R
J Med Virol; 2022 Nov; 94(11):5465-5474. PubMed ID: 35794065
[TBL] [Abstract][Full Text] [Related]
17. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
[TBL] [Abstract][Full Text] [Related]
18. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.
Buti M; Roade L; Riveiro-Barciela M; Esteban R
Liver Int; 2020 Feb; 40 Suppl 1():15-21. PubMed ID: 32077604
[TBL] [Abstract][Full Text] [Related]
20. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]